Arctic Bioscience AS

Arctic Bioscience AS

OOSL:ABS
2.50
NOK
-0.26
(-9.42%)
87.34MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.02
1.24
0.84
0.88
1.4
1.33
1.71
1.49
- -
Basic EPS, GAAP
-0.07
-0.16
-0.93
-1.75
-1.39
-1.79
-1.89
-1.52
- -
Free Cash Flow per Basic Share
- -
- -
-1.45
-3.12
-5.52
-2.56
-3.79
-1.68
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.9
2.63
2.63
13.19
11.79
10.19
8.31
6.44
5.77
Tangible Book Value per Share
0.15
1.59
1.22
10.78
7.39
4.65
0.53
-1.45
-2.12
Basic Weighted Avg Shares
24
24
24
24
24
25
25
27
27
Sales/Revenue/Turnover
25
30
20
22
34
34
43
40
- -
Operating Margin (%)
-4.63
-10.26
-105.75
-188.6
-109.1
-143.96
-109.9
-83.41
- -
Depreciation Expense
1
1
1
3
4
5
5
5
- -
Net Income, GAAP
-2
-4
-23
-43
-34
-46
-48
-41
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-6.88
-13.28
-110.21
-197.91
-99.28
-134.86
-110.23
-102.32
- -
Working Capital
9
43
30
246
158
94
-10
-34
-36
LT Debt
8
7
7
- -
- -
2
- -
27
43
Total Equity
22
64
64
321
287
259
211
173
155
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-9.3
-35.34
-22.15
-11.2
-16.68
-20.43
-21.36
- -

Capital Structure

NOK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
27
36
37
LT Borrowings
12
27
43
LT Finance Leases
16
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
91
88
87

Working Capital

NOK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
55
49
54
Cash, Cash Equivalents & STI
2
- -
- -
Accounts Receivable, Net
11
10
11
Inventories
33
30
35
Total Current Liabilities
67
83
90
Payables & Accruals
- -
- -
- -
ST Debt
27
36
37
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
68.96%
-17.67%
Free Cash Flow
- -
27.25%
-52.79%
Net Income, GAAP
- -
18.61%
-14.41%
Sales/Revenue/Turnover
- -
16.76%
-7.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
43
2025
- -
- -
40
2026
- -
- -
- -

Semi-annual Earnings Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.89
2025
- -
- -
-1.52
2026
- -
- -
- -

Semi-annual Dividends Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Christer Ludvig Valderhaug
Full Time Employees
19
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Industrivegen 42 Orsta MR Norway 6155
IPO Date
Feb 24, 2021
Business
Arctic Bioscience AS (ABS.OL) is a clinical-stage biotechnology company that develops, manufactures and commercializes pharmaceutical and nutraceutical products based on bioactive marine membrane lipids derived primarily from Norwegian spring-spawning herring roe sourced through MSC-certified fisheries; its pharmaceutical pipeline centers on HRO350, an investigational oral drug candidate for mild-to-moderate psoriasis targeting a large global market with unmet needs, while nutraceuticals include high-DHA Omega-3 phospholipid extracts, herring caviar oils and proteins sold globally in bulk B2B formats or as finished goods under the Romega brand for premium consumer applications. Founded in 2011 and headquartered in Ørsta on the northwest coast of Norway with additional offices in Oslo Science Park and international presence in the US and Canada, the company operates in the health and life sciences sector serving healthcare providers, nutraceutical manufacturers and end consumers with innovative marine-derived therapies for autoimmune disorders and premium omega-3 supplements. In January 2025, Arctic Bioscience secured NOK 30 million in long-term funding comprising a NOK 15 million loan from Innovation Norway guaranteed by the European Investment Fund and a NOK 15 million convertible loan from existing shareholders and new Icelandic investors to achieve cash positivity amid 30% year-over-year sales growth in 2024 and cost reduction measures; the HeROPA Phase IIb trial for HRO350 advances toward 12-month readout by end of Q1 2026 with potential Phase III partnerships pending positive results, building on the 2023 acquisition of Arctic Algae AS to enhance micro-algae extraction capabilities for expanded marine lipid applications.